Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRK1 | P41145 | 2/20 | 0.51 |
| ▸ | HRH1 | P35367 | 4/20 | 0.51 |
| ▸ | CCR3 | P51677 | 3/20 | 0.51 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.51 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.50 |
| ▸ | EPHX2 | P34913 | 6/20 | 0.49 |
| ▸ | SLC5A7 | Q9GZV3 | 1/20 | 0.43 |
| ▸ | GAA | P10253 | 1/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19023393 | 0.88 | OPRK1 (0.52) | OPRK1HRH1EPHX2SLC5A7GAA | |
| SCHEMBL12985373 | 0.87 | HRH1 (0.53) | OPRK1HRH1CCR3KCNH2DGAT1 | |
| SCHEMBL5931900 | 0.87 | EPHX2 (0.52) | OPRK1HRH1EPHX2SLC5A7MEN1 | |
| SCHEMBL3612680 | 0.87 | OPRK1 (0.54) | OPRK1HRH1KCNH2EPHX2SLC5A7 | |
| SCHEMBL3965935 | 0.85 | THRA (0.54) | OPRK1HRH1CCR3KCNH2DGAT1 | |
| SCHEMBL19023332 | 0.85 | OPRK1 (0.49) | OPRK1HRH1EPHX2SLC5A7MEN1 | |
| SCHEMBL5931431 | 0.83 | EPHX2 (0.62) | HRH1CCR3KCNH2EPHX2MEN1 | |
| SCHEMBL3292130 | 0.81 | OPRK1 (0.49) | OPRK1HRH1CCR3EPHX2MEN1 | |
| SCHEMBL19610260 | 0.81 | CHRM3 (0.53) | OPRK1KCNH2EPHX2MEN1KMT2A | |
| SCHEMBL18586407 | 0.81 | OPRK1 (0.47) | OPRK1HRH1KCNH2EPHX2SLC5A7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060160851-A1 | Substituted piperidine carbamates | NOVO NORDISK A/S (DK) | 2006-07-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060160851-A1 | Substituted piperidine carbamates | LIPE, PNLIP, LIPC | OPRK1 2335/4885HRH1 730/4885CCR3 2468/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.